{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.7","upperLimit":"27.2","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"PFS is defined as time from initiation of protocol treatment to disease progression, recurrence, death from any cause, or date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Palbociclib)"}],"paramType":"NUMBER","populationDescription":"Three patients did not receive any protocol therapy and are excluded from this analysis.","reportingStatus":"POSTED","timeFrame":"At 6 months","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}